MA56524A - Vecteurs d'arénavirus pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées - Google Patents

Vecteurs d'arénavirus pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées

Info

Publication number
MA56524A
MA56524A MA056524A MA56524A MA56524A MA 56524 A MA56524 A MA 56524A MA 056524 A MA056524 A MA 056524A MA 56524 A MA56524 A MA 56524A MA 56524 A MA56524 A MA 56524A
Authority
MA
Morocco
Prior art keywords
hbv
vaccines
hepatitis
virus
arenavirus vectors
Prior art date
Application number
MA056524A
Other languages
English (en)
Inventor
Daniel Boden
Helen Horton
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA56524A publication Critical patent/MA56524A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA056524A 2019-06-18 2020-06-18 Vecteurs d'arénavirus pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées MA56524A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962862813P 2019-06-18 2019-06-18

Publications (1)

Publication Number Publication Date
MA56524A true MA56524A (fr) 2022-04-27

Family

ID=71728807

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056524A MA56524A (fr) 2019-06-18 2020-06-18 Vecteurs d'arénavirus pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées

Country Status (6)

Country Link
US (1) US20220226467A1 (fr)
EP (1) EP3986455A1 (fr)
AU (1) AU2020297011A1 (fr)
CA (1) CA3143421A1 (fr)
MA (1) MA56524A (fr)
WO (1) WO2020255023A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115197965A (zh) * 2015-06-10 2022-10-18 霍欧奇帕生物科技有限公司 Hpv疫苗
EP4458975A3 (fr) 2019-09-30 2025-02-12 Gilead Sciences, Inc. Vaccins contre le vhb et méthodes de traitement du vhb

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573449B (zh) * 2006-08-14 2013-09-18 浦项工大产学协力团 用于治疗慢性乙型肝炎的dna疫苗及其制备方法
LT2604695T (lt) 2007-12-27 2022-12-12 Universität Zürich Replikacijos defektų turintys arenaviruso vektoriai
WO2014140301A1 (fr) 2013-03-15 2014-09-18 Université De Genève Vaccins anti-mycobactériens
RS60937B1 (sr) * 2014-11-13 2020-11-30 Univ Geneve Tri-segmentirani arenavirusi kao vektori za vakcinu
CN115197965A (zh) * 2015-06-10 2022-10-18 霍欧奇帕生物科技有限公司 Hpv疫苗
CN108779472B (zh) * 2015-11-04 2022-09-09 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
EP3373959B1 (fr) 2015-11-12 2022-06-29 Hookipa Biotech GmbH Particules d'arenavirus en tant que vaccins contre le cancer
NZ747635A (en) 2016-03-28 2024-05-31 Ichor Medical Systems Inc Method and apparatus for delivery of therapeutic agents
EA202091513A1 (ru) * 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение

Also Published As

Publication number Publication date
EP3986455A1 (fr) 2022-04-27
CA3143421A1 (fr) 2020-12-24
WO2020255023A1 (fr) 2020-12-24
US20220226467A1 (en) 2022-07-21
AU2020297011A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
MA51311A (fr) Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
MA56535A (fr) Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
MA51292A (fr) Méthodes et appareil pour l'administration de vaccins contre le virus de l'hépatite b (vhb)
MA50524A (fr) Nouveaux indole-2-carboxamides à substitution amino-thiazole hautement actifs agissant contre le virus de l'hépatite b (vhb)
MA50813A (fr) Vaccins contre le virus d'epstein-barr
MA50520A (fr) Nouveaux indole-2-carboxamides à substitution pyrazolo-pipéridine hautement actifs agissant contre le virus de l'hépatite b (vhb)
MA56534A (fr) Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb)
EP3439696A4 (fr) Vaccin thérapeutique contre le virus de l'hépatite b (vhb) utilisant l'antigène nucléocapsidique du vhb
EP3668520A4 (fr) Vaccins à arnm modifiés codant pour des glycoprotéines du virus de l'herpès simplex et leurs utilisations
PH12019500788A1 (en) Engineered meganucleases specific for recgonition sequences in the hepatitis b virus genome
DK3837366T3 (da) Hepatitis b-virus (hbv) dsrna-agenters sammensætning og fremgangsmåder til deres anvendelse
WO2015173208A3 (fr) Oligomères et conjugués d'oligomères
EP3710049A4 (fr) Vaccin thérapeutique contre le virus de l'hépatite b (vhb) utilisant les régions pres1 et/ou pres2 et/ou s-hbsag du vhb de la protéine d'enveloppe du vhb
MA51312A (fr) Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb)
ZA202206789B (en) Varicella-zoster virus vaccine and application thereof
EP3334833A4 (fr) Vaccins du virus de l'herpès de dinde recombinant et utilisations de celui-ci
IL273093A (en) Combination of drugs for the treatment of hepatitis B virus type HBV patients using Parafoxvirus Obis (PPVO) and at least one other antiviral agent
IL255366B (en) Reagents for the treatment of hepatitis B infection and their use
IL290924A (en) Vaccines for hepatitis b virus
EP4055030A4 (fr) Polypeptides de capside virale
MA56533A (fr) Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1
EP4048682A4 (fr) Vaccins améliorés contre le papillomavirus respiratoire récurrent (prp) et leurs procédés d'utilisation
HK40074161A (en) Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof
MA56536A (fr) Administration de nanoparticules lipidiques ou de liposomes de vaccins contre le virus de l'hépatite b (vhb)
HK40074164A (en) Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai